Pulmicort Linked To Increased Risk Of Death Among Infants: Study

European researchers warn that the long-term side effects of Pulmicort, which is used to prevent bronchopulmonary dysplasia among extremely preterm infants, may actually increase their risk of death. 

The study was published last week in the New England Journal of Medicine, seeking to determine how inhaled glucocortocoids affected the neurodevelopment of preterm infants.

According to the findings, inhaled budesonide-based glucocorticoids like Pulmicort did not appear to affect the rate of neurodevelopmental disability among infants. However, infants treated with the medication appeared to have higher rates of mortality.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The study involved 863 infants who were born between 23 weeks and 28 weeks, considered extremely preterm. About half were given inhaled budesonide and half were given a placebo within 24 hours after birth. Researchers were initially looking for the development of cerebral palsy, cognitive delays, deafness or blindness developing among the infants in the study.

The treatments are given as a mean to prevent bronchopulmonary dysplasia (BPD), which is a form of chronic lung disease which mostly affects premature infants. In most cases, infants recover from BPD on their own, but in some cases it can cause inflammation and scarring of the lungs, resulting in long-term breathing problems. In most cases, the illness is caused by mechanical ventilation and long-term oxygen use.

According to the findings, there was no statistically significant difference in neurodevelopmental disability among the infants given Pulmicort or a placebo by the time they reached age 2. However, infants in the budesonide group had a 37% increased risk of death, with 82 of 413 infants given the drug dying, compared to only 58 of 400 infants given a placebo.

“Among surviving extremely preterm infants, the rate of neurodevelopmental disability at 2 years did not differ significantly between infants who received early inhaled budesonide for the prevention of bronchopulmonary dysplasia and those who received placebo, but the mortality rate was higher among those who received budesonide,” the researchers concluded.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL
Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL (Posted yesterday)

In advance of a a conference this week, lawyers report that progress is being made to prepare a group of federal Gardasil vaccine lawsuits for early test trials, to help gauge how juries may respond to certain evidence and testimony that will be repeated throughout the litigation.

Enfamil Lawsuit Claims Preemie Developed NEC After Being Fed Cow's Milk-Based Infant Formula
Enfamil Lawsuit Claims Preemie Developed NEC After Being Fed Cow's Milk-Based Infant Formula (Posted 2 days ago)

Cow's milk-based infant formula products are dangerous for premature infants, according to a mother's recent Enfamil lawsuit, filed after her newborn developed necrotizing enterocolitis and suffered through surgery and continuing negative health effects.

Ozempic MDL Lawsuits Reassigned To New Judge For Further Pretrial Proceedings
Ozempic MDL Lawsuits Reassigned To New Judge For Further Pretrial Proceedings (Posted 5 days ago)

All lawsuits over Ozempic, Mounjaro, Wegovy and other GLP-1 RA drugs to U.S. District Judge Karen S. Marston, following the death last month of the judge originally appointed to preside over all claims involving stomach paralysis and other gastrointestinal injuries.